Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

PARP/Immunotherapy Combo Shows Promise in Recurrent Ovarian Cancer

Angelica Welch
Published: Wednesday, Sep 05, 2018

Panagiotis A. Konstantinopoulos, MD, PhD

Panagiotis A. Konstantinopoulos, MD, PhD
PARP inhibitors have made a splash in the ovarian cancer landscape, particularly for those with BRCA-mutated tumors. The benefit of these agents as monotherapy has been limited in the platinum-resistant/refractory settings, but there may be hope in combination with immunotherapy, according to Panagiotis A. Konstantinopoulos, MD, PhD.

, Konstantinopoulos, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, and lead TOPACIO/KEYNOTE-162 investigator, discussed the findings of the study and the future for PARP inhibitor combinations and immunotherapy overall in ovarian cancer.

OncLive: Please provide some background information on this study.

Konstantinopoulos: Platinum-resistant/refractory ovarian cancer is an important unmet need, as there are very limited treatment options for these patients. Bevacizumab (Avastin) in combination with chemotherapy is currently FDA approved based on the AURELIA study, which was done in patients with up to 2 prior lines of chemotherapy. In patients with platinum-resistant disease, PARP inhibitors have shown very limited activity as monotherapy. In patients with BRCA-mutated platinum-resistant disease, the ORR is 25% to 30%, which has led to their FDA approval. However, outside that setting, in BRCA wild-type, platinum-resistant disease, the ORR is only 5%. In BRCA-mutated platinum-refractory disease, the ORR is 0% to 14%.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication